BPG is committed to discovery and dissemination of knowledge
Letter to the Editor
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Aug 27, 2025; 17(8): 108160
Published online Aug 27, 2025. doi: 10.4240/wjgs.v17.i8.108160
Adjuvant chemotherapy for gallbladder cancer: Current evidence, controversies, and future directions
Jin-Wei Dai, Yi-Xuan Xing, Nian-Zhe Sun
Jin-Wei Dai, Department of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Jin-Wei Dai, Yi-Xuan Xing, Nian-Zhe Sun, National Clinical Research Center of Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Yi-Xuan Xing, Department of Emergency, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Nian-Zhe Sun, Department of Orthopedics, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Co-corresponding authors: Yi-Xuan Xing and Nian-Zhe Sun.
Author contributions: Dai JW wrote the first draft, developed the main ideas, and led revisions; Sun NZ and Xing YX provided critical feedback, improved the structure, and added key examples, they contributed equally to this manuscript as co-corresponding authors.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Nian-Zhe Sun, MD, PhD, Department of Orthopedics, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha 410008, Hunan Province, China. sunnzh201921@sina.com
Received: April 7, 2025
Revised: April 24, 2025
Accepted: June 20, 2025
Published online: August 27, 2025
Processing time: 141 Days and 1.2 Hours
Core Tip

Core Tip: Whether patients with stage II gallbladder cancer should routinely receive adjuvant chemotherapy after surgery remains uncertain. The analysis by Kim et al, based on National Cancer Database data, found no statistically significant survival benefit associated with chemotherapy in these patients. However, the results should not be hastily interpreted as evidence against chemotherapy altogether. Instead, clinicians must consider individualized treatment decisions based on pathological features and the patient’s overall health condition. This article further evaluated the strengths and weaknesses of Kim et al’s research design. It recommended conducting future studies, ideally prospective clinical trials or refined retrospective analyses, to better clarify chemotherapy’s role in this context.